Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs JPMorgan Chase & Co (JPM) Price & Performance

Incyte CorporationTrade
JPMorgan Chase & CoTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs JPMorgan Chase & Co — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while JPMorgan Chase & Co trades at $365.41 (market cap $962.37B). The key difference: JPMorgan Chase & Co is far larger — about 39.2× Incyte Corporation's market cap, and JPMorgan Chase & Co pays a 1.66% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

INCYJPM
Market Cap
$24.54B$962.37B
Sector
HealthFinancials
52-Week High
$129.93$362.04
52-Week Low
$81.61$282.84
Enterprise Value
$20.04B
Volume
10,479,943
Dividend Yield
1.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Incyte Corporation

Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.

The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.

JPMorgan Chase & Co

JPMorgan Chase & Co. (JPM) trades at $365.63, up 1.62% today, with a bullish technical outlook and strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to an estimated $194.9B in 2026. The stock shows robust profitability with a net income margin of 33.38% and ROE of 18.43%, supported by a moderate P/E of 15.51. Analyst consensus is a 'Moderate Buy' with a $374.18 price target, indicating potential upside amid positive sentiment.

JPM offers a solid investment case driven by earnings growth and sector leadership, but faces risks from macroeconomic volatility and geopolitical tensions. The stock's current price near resistance at $366 requires monitoring for breakout potential, while institutional accumulation and CEO insights on economic risks highlight both opportunity and caution for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY

About JPMorgan Chase & Co

JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.

Read more on JPM